Clinical Trial

A Study of APL-10456-Vaccine

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-28
notable Primary completion pushed: 2026-08-02 -> 2027-05-18 2026-05-28
minor Completion moved earlier: 2027-10-21 -> 2027-05-18 2026-05-28
Trial Details
NCT Number NCT07399132
Lead Sponsor Apollo Therapeutics Ltd
Conditions Rhinovirus
Enrollment 144 participants
Start Date 2026-02-16
Primary Completion 2027-05-18 (estimated)
Study Completion 2027-05-18 (estimated)
Updated on ClinicalTrials.gov 2026-05-27